Calendar Companies Compare Analytics Learn Watchlist

Search CatalystAlert

Search for companies, drugs, and catalysts

Loading market movers...

Free biotech catalyst calendar tracking FDA decisions, clinical trial results, and PDUFA dates for biotech stocks.

Quick Links

Catalyst Calendar
Search Companies
Biotech Glossary
Therapeutic Areas

Legal

About
Privacy
Terms

Data Sources

ClinicalTrials.gov
SEC EDGAR
FDA

© 2025 CatalystAlert. All rights reserved.

Not financial advice. Data may be delayed or incomplete.

LB54640 - Phase 2 | RYTM Pipeline | CatalystAlert

LB54640

Phase 2

RHYTHM PHARMACEUTICALS, INC. (RYTM)

19%

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Jan 31

RYTMPhase 2Phase 2

LB54640 Phase 2 Results Expected

LB54640 • Hypothalamic Obesity

Drug Information

Target Indication

Hypothalamic Obesity

Clinical Trial

Last updated: 12/4/2025

Developer

RYTM

RHYTHM PHARMACEUTICALS, INC.

Biotechnology•North America•NASDAQ